- Home
- CCS vs RYTM Comparison
CCS vs RYTM Comparison
Compare CCS & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCS
- RYTM
- Stock Information
- Founded
- CCS 2000
- RYTM 2008
- Country
- CCS United States
- RYTM United States
- Employees
- CCS N/A
- RYTM N/A
- Industry
- CCS Homebuilding
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- CCS Consumer Discretionary
- RYTM Health Care
- Exchange
- CCS Nasdaq
- RYTM Nasdaq
- Market Cap
- CCS 2.7B
- RYTM 3.1B
- IPO Year
- CCS 2014
- RYTM 2017
- Fundamental
- Price
- CCS $81.15
- RYTM $55.56
- Analyst Decision
- CCS Buy
- RYTM Strong Buy
- Analyst Count
- CCS 4
- RYTM 10
- Target Price
- CCS $104.00
- RYTM $63.70
- AVG Volume (30 Days)
- CCS 330.5K
- RYTM 470.5K
- Earning Date
- CCS 01-29-2025
- RYTM 11-05-2024
- Dividend Yield
- CCS 1.28%
- RYTM N/A
- EPS Growth
- CCS 30.75
- RYTM N/A
- EPS
- CCS 10.03
- RYTM N/A
- Revenue
- CCS $4,330,440,000.00
- RYTM $112,530,000.00
- Revenue This Year
- CCS $19.66
- RYTM $63.64
- Revenue Next Year
- CCS $14.46
- RYTM $42.98
- P/E Ratio
- CCS $8.11
- RYTM N/A
- Revenue Growth
- CCS 18.13
- RYTM 81.55
- 52 Week Low
- CCS $74.76
- RYTM $35.17
- 52 Week High
- CCS $108.42
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- CCS 30.92
- RYTM 45.40
- Support Level
- CCS $81.60
- RYTM $54.52
- Resistance Level
- CCS $95.76
- RYTM $58.56
- Average True Range (ATR)
- CCS 2.23
- RYTM 1.90
- MACD
- CCS -0.62
- RYTM -0.65
- Stochastic Oscillator
- CCS 0.00
- RYTM 21.10
About CCS Century Communities Inc.
Century Communities Inc is a construction company that focuses on the residential market. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its own sales representatives and independent real estate brokers. It also advertises directly to potential homebuyers through the Internet, newspapers, and trade publications. The company generates the majority revenue from the Mountain segment.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.